Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis

被引:8
|
作者
Ohashi, Kadoaki [1 ]
Ninomiya, Kiichiro [1 ]
Yoshioka, Hiroshige [2 ,20 ]
Bessho, Akihiro [3 ]
Shibayama, Takuo [4 ]
Aoe, Keisuke [5 ]
Ishikawa, Nobuhisa [6 ]
Kozuki, Toshiyuki [7 ]
Kawai, Haruyuki [8 ]
Kuyama, Shoichi [9 ]
Miyoshi, Seigo [10 ]
Fujitaka, Kazunori [11 ]
Obata, Hideto [12 ]
Tsubata, Yukari [13 ]
Awaya, Yoshikazu [14 ]
Inoue, Masaaki [15 ]
Inoue, Koji [16 ]
Horita, Naokatsu [17 ]
Yanai, Hiroyuki [18 ]
Hotta, Katsuyuki [19 ]
Kiura, Katsuyuki [1 ]
机构
[1] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan
[2] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan
[3] Japanese Red Cross Okayama Hosp, Dept Resp Med, Okayama, Japan
[4] Natl Hosp Org, Dept Resp Med, Okayama Med Ctr, Okayama, Japan
[5] Natl Hosp Org, Dept Med Oncol, Yamaguchi Ube Med Ctr, Ube, Yamaguchi, Japan
[6] Hiroshima Prefectural Hosp, Dept Resp Med, Hiroshima, Japan
[7] Natl Hosp Org, Shikoku Canc Ctr, Dept Thorac Oncol & Med, Shikoku, Ehime, Japan
[8] Okayama Saiseikai Gen Hosp, Dept Internal Med, Okayama, Japan
[9] Iwakuni Med Ctr, Dept Resp Med, Iwakuni, Japan
[10] Ehime Univ, Grad Sch Med, Dept Cardiol Pulmonol Hypertens & Nephrol, Matsuyama, Ehime, Japan
[11] Hiroshima Univ Hosp, Dept Resp Med, Hiroshima, Japan
[12] Yamaguchi Ken Saiseikai Shimonoseki Gen Hosp, Dept Resp Med, Shimonoseki, Yamaguchi, Japan
[13] Shimane Univ, Fac Med, Div Med Oncol & Resp Med, Dept Internal Med, Matsue, Shimane, Japan
[14] Miyoshi Cent Hosp, Dept Resp Med, Saitama, Japan
[15] Shimonoseki City Hosp, Dept Chest Surg, Shimonoseki, Yamaguchi, Japan
[16] Ehime Prefectural Cent Hosp, Dept Resp Med, Matsuyama, Ehime, Japan
[17] Kure Kyosai Hosp, Dept Resp Med, Kure, Hiroshima, Japan
[18] Okayama Univ Hosp, Dept Pathol, Okayama, Japan
[19] Okayama Univ Hosp, Ctr Innovat Clin Med, 2-5-1 Shikata Cho Kita Ward, Okayama 7008558, Japan
[20] Kansai Med Univ Hosp, Dept Thorac Oncol, Hirakata, Osaka, Japan
关键词
Epidermal growth factor receptor mutations; Performance status; Human epidermal growth factor receptor-2; Time-To-Treatment failure; GROWTH-FACTOR RECEPTOR; ACQUIRED-RESISTANCE; TRASTUZUMAB EMTANSINE; GENE-MUTATIONS; PHASE-II; CANCER; MUTANT; AMPLIFICATION; OVEREXPRESSION; ADENOCARCINOMA;
D O I
10.1016/j.lungcan.2020.09.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are standard treatment for EGFR-mutated non-small-cell lung carcinoma (NSCLC); however, a biomarker to predict their efficacy has not been established. Although human epidermal growth factor receptor-2 (HER2) aberrations constitute a potential mechanism for acquired resistance to EGFR-TKIs, the impact of HER2 on EGFR-TKI treatment outcomes has not been systematically evaluated. In this post-hoc subgroup study, we examined the impact of HER2 on the effect of EGFR-TKIs in patients with NSCLC harboring EGFR mutations. Materials and Methods: Of 1126 patients with NSCLC enrolled into a prospective cohort study (HER2-CS study), we analyzed data of 356 (32 %) patients with EGFR-mutant tumors. HER2 protein expression levels were determined by immunohistochemistry (IHC) with the gastric cancer criteria. Patients were divided either to an HER2-P group (HER2-IHC2+/3+) or an HER2-N group (HER2-IHC0/1+). We primarily assessed differences in the time-to-treatment failure (TTF) of EGFR-TKI between the groups. Results: The HER2 scoring was as follows: IHC0 (n = 76, 21 %), IHC1+ (n = 199, 56 %), IHC2+ (n = 72, 20 %), and IHC3+ (n = 9, 3 %). The patients' demographics were similar in the HER2-P and HER2-N groups. The HER2-P group showed a significantly shorter EGFR-TKI TTF than the HER2-N group (hazard ratio [HR]: 1.657, 95 % confidence interval [CI]: 1.076-2.552; median: 13.3 vs. 19.1 months). The magnitude of the negative impact of TTF was especially dependent on performance status (PS). HER2 expression significantly deteriorated the TTF in the subgroup with PS 2 (HR: 5.497, 95 % CI: 1.510-20.02), but not in that with better PS (HR: 1.437, 95 % CI: 0.899-2.298) (pinteraction = 0.015). Conclusion: In the current cohort, HER2 protein expression in EGFR-mutant NSCLC may have a negative impact on the effect of EGFR-TKIs, the effect of which was PS dependent.
引用
收藏
页码:83 / 89
页数:7
相关论文
共 50 条
  • [41] Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence
    Wang, Xiaochun
    Goldstein, David
    Crowe, Philip J.
    Yang, Jia-Lin
    ONCOTARGETS AND THERAPY, 2016, 9 : 5461 - 5473
  • [42] EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy
    Wei, Q.
    Shui, Y.
    Zheng, S.
    Wester, K.
    Nordgren, H.
    Nygren, P.
    Glimelius, B.
    Carlsson, J.
    ONCOLOGY REPORTS, 2011, 25 (01) : 3 - 11
  • [43] Hormone Receptor, HER2/NEU and EGFR Expression in Ovarian Carcinoma - is here a Prognostic Phenotype?
    Demir, Lutfiye
    Yigit, Seyran
    Sadullahoglu, Canan
    Akyol, Murat
    Cokmert, Suna
    Kucukzeybek, Yuksel
    Alacacioglu, Ahmet
    Cakalagaoglu, Fulya
    Tarhan, Mustafa Oktay
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (22) : 9739 - 9745
  • [44] EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance
    Kim, Yeseul
    Jee, Seungyun
    Kim, Hyunsung
    Paik, Seung Sam
    Choi, Dongho
    Yoo, Su Hyun
    Shin, Su-Jin
    ONCOLOGIST, 2024, 29 (08) : e1051 - e1060
  • [45] Bispecific radioimmunoconjugates exploit receptor heterogeneity for positron emission tomography of tumors expressing HER2 and/or EGFR
    Kwon, Luke Yongkyu
    Cai, Zhongli
    Al-Mahrouki, Azza
    Reilly, Raymond M.
    ISCIENCE, 2024, 27 (05)
  • [46] Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations
    Imai, Hisao
    Minemura, Hiroyuki
    Sugiyama, Tomohide
    Yamada, Yutaka
    Kaira, Kyoichi
    Kanazawa, Kenya
    Kasai, Takashi
    Kaburagi, Takayuki
    Minato, Koichi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (01) : 119 - 127
  • [47] Quantitative proteomic analysis of HER2 protein expression in PDAC tumors
    Randall, Jamie
    Hunt, Allison L.
    Nutcharoen, Aratara
    Johnston, Laura
    Chouraichi, Safae
    Wang, Hongkun
    Winer, Arthur
    Wadlow, Raymond
    Huynh, Jasmine
    Davis, Justin
    Corgiat, Brian
    Bateman, Nicholas W.
    Deeken, John F.
    Petricoin, Emanuel F.
    Conrads, Thomas P.
    Cannon, Timothy L.
    CLINICAL PROTEOMICS, 2024, 21 (01)
  • [48] Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma
    Nagatsuma, Akiko Kawano
    Aizawa, Masaki
    Kuwata, Takeshi
    Doi, Toshihiko
    Ohtsu, Atsushi
    Fujii, Hirofumi
    Ochiai, Atsushi
    GASTRIC CANCER, 2015, 18 (02) : 227 - 238
  • [49] Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
    Shankaran, Harish
    Zhang, Yi
    Tan, Yunbing
    Resat, Haluk
    PLOS COMPUTATIONAL BIOLOGY, 2013, 9 (08)
  • [50] FLUORESCENCE IN SITU HYBRIDIZATION GENE AMPLIFICATION ANALYSIS OF EGFR AND HER2 IN PATIENTS WITH MALIGNANT SALIVARY GLAND TUMORS TREATED WITH LAPATINIB
    Vidal, Laura
    Tsao, Ming S.
    Pond, Gregory R.
    Cohen, Ezra E. W.
    Cohen, Roger B.
    Chen, Eric X.
    Agulnik, Mark
    Hotte, Sebastien
    Winquist, Eric
    Laurie, Scott
    Hayes, D. Neil
    Ho, James
    Dancey, Janet
    Siu, Lillian L.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2009, 31 (08): : 1006 - 1012